

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

LoVo

RRID:CVCL_0399

Type: Cell Line

Proper Citation

RRID:CVCL_0399

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0399

Proper Citation: RRID:CVCL_0399

Description: Cell line LoVo is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: [PMID:1260746](#), [PMID:3335022](#), [PMID:7104989](#), [PMID:7651727](#), [PMID:8197130](#), [PMID:8464898](#), [PMID:9000147](#), [PMID:9000572](#), [PMID:9290701](#), [PMID:9294210](#), [PMID:9515795](#), [PMID:9715273](#), [PMID:10612807](#), [PMID:10674020](#), [PMID:10737795](#), [PMID:11226274](#), [PMID:11314036](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:11526487](#), [PMID:11668190](#), [PMID:12068308](#), [PMID:12584437](#), [PMID:12615714](#), [PMID:12661003](#), [PMID:15771911](#), [PMID:15900046](#), [PMID:16418264](#), [PMID:16854228](#), [PMID:18258742](#), [PMID:19927377](#), [PMID:19941903](#), [PMID:20164919](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:20831567](#), [PMID:22460905](#), [PMID:24042735](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:25984343](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:32172478](#), [PMID:34320349](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LoVo

Synonyms: LOVO

Cross References: BTO:BTO_0000666, CLO:CLO_0007377, CLO:CLO_0007378, CLO:CLO_0050632, EFO:EFO_0006639, MCCL:MCC:0000293, CLDB:cl3248, CLDB:cl3249, CLDB:cl3250, CLDB:cl4981, AddexBio:C0009011/380, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-229, BCRC:60148, BCRJ:0332, BioGRID_ORCS_Cell_line:405, BioSample:SAMN03470964, BioSample:SAMN03471476, BioSample:SAMN03472104, BioSample:SAMN03472362, BioSample:SAMN03473360, BioSample:SAMN05292432, BioSample:SAMN10988310, cancercellines:CVCL_0399, CCLV:CCLV-RIE 1151, CCRID:1101HUM-PUMC000164, CCRID:3101HUMSCSP514, CCRID:3101HUMTCHu82, CCRID:4201HUM-CCTCC00646, CCTCC:GDC0186, Cell_Model_Passport:SIDM00839, ChEMBL-Cells:ChEMBL3307691, ChEMBL-Targets:ChEMBL614721, CLS:300266, ColonAtlas:LOVO, Cosmic:711256, Cosmic:720330, Cosmic:724842, Cosmic:738931, Cosmic:873702, Cosmic:876724, Cosmic:887220, Cosmic:889534, Cosmic:897741, Cosmic:905003, Cosmic:907790, Cosmic:913886, Cosmic:948858, Cosmic:985997, Cosmic:995396, Cosmic:1043567, Cosmic:1057754, Cosmic:1066209, Cosmic:1122327, Cosmic:1132566, Cosmic:1132691, Cosmic:1184084, Cosmic:1184329, Cosmic:1187308, Cosmic:1223145, Cosmic:1312303, Cosmic:1466817, Cosmic:1479597, Cosmic:1482522, Cosmic:1486133, Cosmic:1524331, Cosmic:1552182, Cosmic:1571770, Cosmic:1609489, Cosmic:1676729, Cosmic:1708412, Cosmic:1803948, Cosmic:1927244, Cosmic:1945867, Cosmic:1995488, Cosmic:2267319, Cosmic:2301996, Cosmic:2389574, Cosmic:2588707, Cosmic:2646767, Cosmic:2651865, Cosmic:2664049, Cosmic:2667975, Cosmic:2760062, Cosmic:2787548, Cosmic:2800576, Cosmic-CLP:907790, DepMap:ACH-000950, DSMZ:ACC-350, DSMZCellDive:ACC-350, ECACC:87060101, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS024NHD, ENCODE:ENCBS080BPN, GDSC:907790, GEO:GSM206517, GEO:GSM274719, GEO:GSM274720, GEO:GSM274729, GEO:GSM513820, GEO:GSM514296, GEO:GSM741268, GEO:GSM784014, GEO:GSM887274, GEO:GSM888349, GEO:GSM1346882, GEO:GSM1374627, GEO:GSM1374628, GEO:GSM1374629, GEO:GSM1374630, GEO:GSM1448163, GEO:GSM1670055, GEO:GSM2550007, GEO:GSM3591765, IARC_TP53:21485, ICLC:HTL99028, IZSLER:BS TCL 205, JCRB:IFO50067, JCRB:JCRB9083, KCB:KCB 200718YJ, KCLB:10229, LiGeA:CCLE_421, LINCS_LDP:LCL-1181, Lonza:1021, MetaboLights:MTBLS227, NCI-DTP:LOVO, PharmacDB:LoVo_856_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_0399, PubChem_Cell_line:CVCL_0399, RCB:RCB1639, SKY/M-FISH/CGH:2878, TKG:TKG 0344, Ubigen:YC-C137, Wikidata:Q54902894

ID: CVCL_0399

Record Creation Time: 20220427T220733+0000

Record Last Update: 20260829T234522+0000

Ratings and Alerts

No rating or validation information has been found for LoVo.

Warning: Discontinued: TKG; TKG 0344

Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 754 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Domagalski M, et al. (2026) Visceral and subcutaneous adipose stem cells modulate colorectal cancer cell progression: direct and indirect contact distinctly accelerate tumor aggressiveness. *Molecular medicine (Cambridge, Mass.)*, 32(1).

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(26), e16557.

Kang Z, et al. (2026) LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. *Genome biology*, 27(1).

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Lee CJ, et al. (2026) The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. *Signal transduction and targeted therapy*, 11(1), 19.

Swift SZ, et al. (2026) Integration of Short- and Long-Read RNA Sequencing Enables the Discovery of Circular RNAs. *Cancer research*, 86(5), 1300.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Duan C, et al. (2026) FUT2-Mediated Fucosylation of OLFM4 Promotes Colon Cancer Cell Differentiation. *Canadian journal of gastroenterology & hepatology*, 2026(1), e7502916.

Zhang X, et al. (2026) Neferine-enhanced Shenling Baizhu Tang potentiates anti-PD-1 therapy in colorectal cancer liver metastasis via CYP2E1-PPAR γ -mediated lipid reprogramming. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 156, 158236.

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(8), 2042.

Zhang Y, et al. (2026) SERPINA3 mediates liver cancer cells escape from chemotherapy-induced neutrophil extracellular trap killing. *Cell reports*, 45(2), 116956.

Ji F, et al. (2026) Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis. *Cell metabolism*, 38(4), 794.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Liu X, et al. (2026) Role of Ca²⁺-Dependent Epithelial-Mesenchymal Transition in Malignant Progression of Colorectal Cancer: Special Focus on REG I²/EDNRB. *Cancer medicine*, 15(4), e71754.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Huang C, et al. (2026) Pregnenolone promotes immune evasion through blocking endogenous retrovirus expression. *Cell metabolism*, 38(5), 981.

Liang J, et al. (2026) DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer. *Cell reports*, 45(8), 117719.

Tolotto V, et al. (2026) Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer. *Molecular oncology*, 20(3), 637.